Sofinnova Partners closes €725M Crossover II fund for European life sciences
Sofinnova Partners closes €725M Crossover II fund to scale European life sciences companies
AI Overview
Sofinnova Partners closed its second crossover fund at €725 million, above its original target.
Why it matters
Sofinnova's €725M close sits alongside larger European crossover funds, giving readers a concrete measure of how late-stage life sciences capital is being assembled.